SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theragenics (TGX) on the up and up
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug who wrote (956)7/8/1998 4:59:00 PM
From: Tulvio Durand  Read Replies (3) of 1055
 
Reacall that # cyclotrons goes from 4 (1997) to 8 (1998) to 14 (1999). Given that R&D is all done and marketing (J&J) is all in place, I see any rise in product capacity as considerably more profitable compared to the original production. Therefore I see 48% earnings growth rate easily doable based on capacity growth alone. But competition is the key, and, right now they have none. Until we see competitive Pd seeds, in quantity, on the market -- 48% growth is very doable. Tulvio
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News